AbbVie Inc. (ABBV) Covered Calls

AbbVie Inc. is a research-based biopharmaceutical company focused on developing advanced therapies for complex and critical health conditions. The company specializes in several key therapeutic areas, including immunology, oncology, neuroscience, eye care, and aesthetics. Through its diverse portfolio of medicines and a robust clinical pipeline, AbbVie aims to deliver innovative solutions that address serious diseases and improve patient outcomes on a global scale.

You can sell covered calls on AbbVie Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for ABBV (prices last updated Fri 4:16 PM ET):

AbbVie Inc. (ABBV) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
231.50 +4.00 230.50 232.35 8.2M 172 402
Covered Calls For AbbVie Inc. (ABBV)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
Feb 20 232.5 2.58 229.77 1.1% 50.2%
Mar 20 230 8.75 223.60 2.9% 29.4%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Core Business and Products

AbbVie Inc. (ABBV) is a global biopharmaceutical leader that originated as a spin-off from Abbott Laboratories in 2013. In 2026, the company has successfully navigated the most significant patent cliff in pharmaceutical history—the loss of exclusivity for its flagship drug, Humira—and has successfully transitioned into a multi-platform growth engine. The company’s operations are centered on five specialized therapeutic pillars:

  1. Immunology: This remains AbbVie's largest segment. While Humira sales have declined due to biosimilar competition, next-generation blockbusters Skyrizi and Rinvoq have taken its place. These therapies are approved for various conditions, including plaque psoriasis, Crohn's disease, and ulcerative colitis, with ongoing expansions into lupus and vitiligo in 2026.
  2. Oncology: AbbVie is a powerhouse in hematologic malignancies with Venclexta and Imbruvica. Following its strategic acquisition of ImmunoGen, the company has integrated a leading Antibody-Drug Conjugate (ADC) platform, anchored by Elahere for ovarian cancer, which is a major growth driver this year.
  3. Neuroscience: This is currently AbbVie's fastest-growing franchise. It features a comprehensive migraine portfolio including Botox Therapeutic, Qulipta, and Ubrelvy, alongside Vraylar for bipolar disorder and a deepening pipeline in Parkinson’s and Alzheimer’s disease.
  4. Aesthetics: Operating through the Allergan Aesthetics brand, AbbVie leads the global market in medical aesthetics with Botox Cosmetic and the Juvederm collection of dermal fillers.

Competitive Landscape

AbbVie competes in an environment defined by rapid innovation, high R&D costs, and aggressive generic or biosimilar entry:

  1. Immunology and Biotech Rivals: In its core immunology markets, AbbVie faces stiff competition from Amgen and Eli Lilly and Company. It also competes with Gilead Sciences in the inflammatory disease and virology spaces.
  2. Oncology Competitors: In the cancer treatment market, AbbVie vies for share with Johnson & Johnson, Merck & Co., and Bristol Myers Squibb. The race for dominance in ADCs also pits them against AstraZeneca and Pfizer.
  3. Specialized Peers: In neuroscience, particularly for complex brain disorders, AbbVie competes with Biogen and Vertex Pharmaceuticals.

Strategic Outlook and Innovation

As of February 2026, AbbVie has returned to robust top-line growth, proving the durability of its post-Humira strategy. The company is currently executing a $100 billion U.S.-based R&D pledge, focusing on "modality expansion" where they combine traditional small molecules with advanced biologics, bispecific antibodies, and ADCs. A key highlight for 2026 is the expansion of the "Agentic AI" clinical trial platform, which has reduced the time for drug discovery and patient recruitment by nearly 30%. Strategically, AbbVie is also strengthening its domestic supply chain with new manufacturing facilities in Arizona to ensure the secure production of its biologics. With a strong commitment to shareholder returns through its Dividend King status and a pipeline targeting over 20 new approvals through 2027, AbbVie is positioned as a resilient and high-yielding leader in the global healthcare sector.